Introduction
============

Micropapillary carcinomas (MPCs) are a histological special type of breast cancer accounting for up to 7% of all invasive breast carcinomas [@b1]. These tumours display a unique growth pattern featuring clusters of tumour cells displaying inverted polarity immersed in a spongy stroma, and often display extensive vascular invasion [@b1]. Microarray-based comparative genomic hybridization (aCGH) analysis carried out by our group has revealed that pure and mixed MPCs are remarkably similar at the genetic level [@b2] and harbour a constellation of genetic aberrations that is distinct from that of grade- and oestrogen receptor (ER)-matched invasive carcinomas of no special type (IC-NSTs, also known as invasive ductal carcinomas of no special type) [@b2],[@b3]. Our genomic analysis, however, did not identify any specific genomic aberration that may explain the distinctive morphology and clinical behaviour of MPCs.

Some histological special types of breast cancer have been shown to be underpinned by highly recurrent fusion genes or somatic mutations (reviewed in refs 4 and 5). For instance, adenoid cystic carcinomas and secretory carcinomas of the breast have been shown to be characterized by recurrent specific chromosomal translocations that lead to the formation of the recurrent fusion genes *MYB--NFIB* [@b6] and *ETV6--NTRK3* [@b7], respectively, while lobular carcinomas are underpinned by E-cadherin loss of function [@b4],[@b8],[@b9].

Massively parallel sequencing studies are providing a comprehensive characterization of the repertoire of mutations and fusion genes in different types of cancer [@b10]--[@b16]. In breast cancer, RNA-sequencing studies have identified a panoply of expressed fusion genes [@b12]--[@b14],[@b17], although the majority of these appear to exist at very low prevalence or represent private events (ie identified only in the index case) [@b12],[@b17],[@b18]. It is currently believed that most of these fusion genes may be mere passenger events [@b12],[@b19]. Recently, however, RNA sequencing has identified two classes of recurrent gene rearrangements in IC-NSTs, involving genes encoding microtubule-associated serine-threonine kinase (MAST) and members of the Notch family [@b17]. Furthermore, the presence of a chromosomal rearrangement resulting in the formation of a potentially functionally relevant *MAGI3--AKT3* chimeric protein has been described in a subset of breast cancers [@b15].

Given the previous identification of pathognomonic fusion genes and somatic mutations in histological special types of breast cancer and the recent identification of recurrent expressed fusion genes in breast cancer, the aims of this study were to determine (i) if MPCs harbour recurrent mutations affecting 273 genes, either recurrently mutated in breast cancer or DNA repair-related, or (ii) if MPCs are underpinned by highly-recurrent expressed fusion genes. Furthermore, we sought to determine the biological significance of selected fusion genes identified in MPCs *in vitro*.

Materials and methods
=====================

Tumour samples
--------------

The study design is illustrated in Supplementary [Figure 1](#fig01){ref-type="fig"} and power calculations are described in the Supplementary methods. In brief, two cohorts of MPCs were analysed: 16 formalin-fixed, paraffin-embedded (FFPE) MPCs (Table[1](#tbl1){ref-type="table"}), five of which had matched frozen material, and 14 additional FFPE MPCs, employed as a validation cohort. In addition, control groups of 16 IC-NSTs and 14 IC-NSTs grade- and ER-matched to the two series of MPCs were employed. Finally, an additional 48 grade 3 IC-NSTs were retrieved from the authors\' institutions and surveyed for the presence of specific fusion transcripts (Supplementary methods and Supplementary Table 1). This study was approved by the authors\' local research ethics committees.

![Microarray-based comparative genomic hybridization frequency plots and RNA-sequencing circos plots of micropapillary carcinomas of the breast. (A) Frequency plot of copy number gains and losses in 16 micropapillary carcinomas of the breast. The proportion of tumours in which each bacterial artificial chromosome (BAC) clone is gained (green bars) or lost (red bars) is plotted (*y*-axis) for each BAC clone according to its genomic position (*x*-axis). (B) Frequency plot of amplifications in 16 micropapillary carcinomas of the breast. The proportion of tumours in which each BAC clone is amplified (green bars) is plotted (*y*-axis) for each BAC clone according to its genomic position (*x*-axis). The red dashed line indicates the threshold for recurrent events. (C) High-confidence validated expressed fusion genes are plotted in purple and high-confidence non-validated fusions in grey, linking the genomic locus of each partner of the fusion genes. Genome plots, based on the 32K aCGH data, are plotted in the inner circle (green, copy number gains; red, copy number losses; black, no copy number changes). MPC, micropapillary carcinoma of the breast.](path0232-0553-f1){#fig01}

###### 

Main cohort of 16 microdissected MPCs subjected to microarray-based comparative genomic hybridization and Sequenom MassARRAY OncoCarta analysis. Five of the cases were subjected to RNA massively parallel sequencing due to the availability of a frozen specimen

  Sample   Pure/mixed   Specimen type   Grade   ER         PR         HER2       RNA-seq   Mutation[\*](#tf1-1){ref-type="table-fn"}
  -------- ------------ --------------- ------- ---------- ---------- ---------- --------- -------------------------------------------
  MPC10    Pure         Frozen          3       Positive   Positive   Negative   Y         None
  MPC08    Pure         Frozen          2       Positive   Positive   Negative   Y         None
  MPC70    Pure         Frozen          2       Positive   Positive   Negative   Y         None
  MPC72    Pure         Frozen          3       Positive   Negative   Negative   Y         None
  MPC71    Pure         Frozen          3       Positive   Positive   Positive   Y         None
  MPC37    Mixed        Frozen          3       Positive   Positive   Negative   NP        None
  MPC06    Pure         FFPE            2       Positive   Positive   Negative   NP        None
  MPC11    Pure         FFPE            2       Positive   Positive   Negative   NP        None
  MPC02    Pure         FFPE            2       Positive   Positive   Negative   NP        None
  MPC04    Pure         FFPE            3       Positive   Negative   Negative   NP        None
  MPC01    Pure         FFPE            2       Positive   Positive   Negative   NP        None
  MPC23    Pure         FFPE            3       Positive   Negative   Negative   NP        None
  MPC25    Mixed        FFPE            2       Positive   Positive   Negative   NP        *PIK3CA* H1047R
  MPC45    Mixed        FFPE            3       Positive   Positive   Positive   NP        None
  MPC38    Mixed        FFPE            3       Positive   Positive   Negative   NP        None
  MPC53    Mixed        FFPE            3       Negative   Negative   Positive   NP        None

ER, oestrogen receptor; FFPE, formalin-fixed, paraffin-embedded; NP, not performed; PR, progesterone receptor; RNA-seq, paired-end massively parallel mRNA sequencing; Y, yes.

Mutations in the hotspot regions of 19 genes assessed by the Sequenom OncoCarta v1.0.

Immunohistochemistry
--------------------

Representative sections of each case were subjected to immunohistochemical assessment using antibodies against epithelial membrane antigen, ER, progesterone receptor (PR), and HER2 as previously described [@b2],[@b3] and were reviewed by at least two pathologists (CM, AS, and/or JSR-F), using previously defined scoring systems and cut-offs [@b2],[@b3],[@b20] (Supplementary methods and Supplementary Table 2).

Microdissection, DNA extraction, and RNA extraction
---------------------------------------------------

Representative 8-µm-thick sections of the MPCs and IC-NSTs were subjected to microdissection with a sterile needle under a stereomicroscope (Olympus SZ61, Tokyo, Japan) to ensure a percentage of tumour cells greater than 90%, as previously described [@b3],[@b21]. DNA extraction, quantification, and quality control assessment were performed as previously described [@b3],[@b21] (Supplementary methods). From eight of the 16 MPCs microdissected, adjacent normal breast tissue was successfully microdissected.

Microarray comparative genomic hybridization (aCGH)
---------------------------------------------------

Sixteen MPCs and 16 grade-, ER-, and HER2-matched IC-NSTs were subjected to aCGH analysis using a platform that comprised ∼32 000 BAC clones tiled across the genome [@b22]. This platform has been shown to be as robust as, and to have comparable resolution to high-density oligonucleotide arrays [@b23]--[@b25]. DNA labelling, array hybridization, image acquisition, and data analysis were performed as previously described [@b3],[@b22],[@b26],[@b27] (Supplementary methods). Data, the analysis history, script, and code are available at <http://rock.icr.ac.uk/collaborations/Mackay/Micropapillary>.

Mutation screening and validation
---------------------------------

Sixteen MPCs and 16 grade-, ER-, and HER2-matched IC-NSTs were subjected to hotspot mutation screening of 19 known cancer genes using the OncoCarta Panel v 1.0 (Sequenom, San Diego, CA, USA) and validated using Sanger sequencing as previously described [@b22],[@b27]. For eight of these cases, sufficient DNA from tumour and normal breast was available for targeted capture massively parallel sequencing analysis using a bait library targeting 273 genes either recurrently mutated in breast cancer or DNA repair-related genes as previously described [@b2],[@b28]--[@b35] (Supplementary methods and Supplementary Table 3).

Paired-end massively parallel RNA sequencing
--------------------------------------------

Five pure frozen MPCs were subjected to mRNA massively parallel sequencing, which was performed according to the standard Illumina mRNA paired-end library protocol (Illumina Inc, San Diego, CA, USA) as previously described [@b36]. Paired-end sequencing was performed using 2 × 54 bp cycles on the Genome Analyser IIx (Illumina; Supplementary methods). Data were aligned to the genome and transcriptome using Bowtie [@b37]. Mate-pairs supporting novel chimeric transcripts were identified using ChimeraScan version 4.0.3.0 as previously described [@b17],[@b37]. High-confidence chimeric transcripts were nominated subsequent to further filtering to remove multi-mapping reads and to exclude false-positive nominations [@b37].

Reverse-transcription PCR (RT-PCR), PCR, and Sanger sequencing validation
-------------------------------------------------------------------------

Nominated fusion genes were validated in five index cases by RT-PCR and Sanger sequencing as previously described [@b18] (Supplementary methods). Validated in-frame and out-of-frame fusion genes with recurrent partners found in independent datasets [@b12],[@b15]--[@b17] were screened at the cDNA level in an independent cohort of MPCs (*n =* 14), grade- and ER-matched IC-NSTs (*n =* 14), and grade 3 IC-NSTs (*n =* 48) using RT-PCR or quantitative real-time PCR (qRT-PCR; Supplementary methods).

Constructs for functional analyses
----------------------------------

The *SLC2A1--FAF1* and *BCAS4--AURKA* fusion open reading frames (ORFs) were PCR-amplified from the index tumour (MPC10) and cloned into a mammalian expression vector pCMVentry, with a C-terminal DDK tag (OriGene, Rockville, MD, USA). Full-length expression constructs of *FAF1*, *AURKA*, and *RAE1* with DDK tags were obtained from OriGene. Expression of the fusion and wild-type protein constructs was detected with the anti-DDK monoclonal antibody 4C5 (Origene) by western blotting of 20 µg of whole cell protein lysate as previously described [@b38]. Sequences of the ORFs are available at <http://rock.icr.ac.uk/collaborations/Mackay/Micropapillary>.

Cell line models
----------------

The ER-positive breast cancer cell lines, MCF7, BT474, T47D, and ZR75.1, whose phenotypic characteristics and patterns of copy number aberrations are consistent with those of the MPCs (Supplementary Table 4), and 12 *HER2*-amplified cell lines (JIMT1, UACC812, UACC893, VP229, SKBR3, ZR75.30, HCC1569, HCC1954, MDA-MB-453, MDA-MB-361, SUM225, and SUM190) were included in this study. The sources, growth conditions, and authentication methods are described in the Supplementary methods.

Functional assessment of in-frame fusion genes
----------------------------------------------

Cloned *SLC2A1-FAF1* and *BCAS4-AURKA* fusions, full-length 3′ partner gene constructs or empty vectors were transfected into four ER-positive breast cancer cell lines (MCF7, BT474, T47D, and ZR75.1) using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). Antibiotic selection was performed as previously described [@b38], and cell populations were assessed every 24 h, for 9 days, using the CellTiter-Glo® cell viability assay (Promega, Madison, WI, USA) [@b38], with each reading normalized to day 1 to determine the fold change (Supplementary methods).

Functional assessment of out-of-frame fusion genes
--------------------------------------------------

Short-interfering RNA (siRNA) silencing of *CDK12* was performed as previously described [@b38],[@b39]. Briefly, MCF7, T47D, and SUM149 breast cancer cells were transfected with siGENOME SMARTpools (each containing four distinct siRNAs targeting each gene), a non-targeting negative control siRNA (siCON), and a positive control siRNA targeting *PLK1* (siCDK12: M-004031-03; siControl: D-001206-14; siPLK1: M-003290-01; Fermentas, Germany). Transfection mixes contained 50 n[m]{.smallcaps} siRNA in a final volume of 100 µl, together with Lipofectamine RNAiMAX reagent (Invitrogen). CDK12 silencing was confirmed at the protein level by western blotting using an anti-CDK12 antibody (ab37914; Abcam, Cambridge, MA, USA).

Long-term survival assay
------------------------

Long-term 14-day survival assays were performed using six-well plates in triplicate as previously described [@b38],[@b39]. The sulforhodamine B (SRB) (Sigma) assay was employed as readout as described previously [@b38],[@b39] (Supplementary methods). The PARP inhibitor BMN673 was a kind gift from BioMarin Pharmaceuticals (San Rafael, CA, USA), and olaparib (AZD2281/KU0058948) was obtained from SelleckBio (Munich, Germany).

Analysis of RAD51 foci formation
--------------------------------

Nuclear RAD51 and phospho-γ-H2AX foci were visualized and quantified as previously described [@b38],[@b39] and used as surrogate markers for induction of DNA double-strand breaks (DSBs) and competent homologous recombination (HR) DNA repair, respectively (Supplementary methods).

Statistical analyses
--------------------

The statistical analysis methods employed are described in the Supplementary methods.

Results
=======

The landscape of gene copy number aberrations and somatic mutations in MPCs
---------------------------------------------------------------------------

Genome-wide aCGH profiling of 16 MPCs revealed extensive changes in the genome, ranging from 10.4% to 54.3% of BACs showing either gains or losses (mean: 28.5%; median: 28.9%). Consistent with the results of our previous studies [@b2],[@b3],[@b40], the most frequent recurrent changes included gains of 1q, 8q, 17q, and 20q, and losses of 1p 8p, 13q, 16q, and 22q ([Figure 1](#fig01){ref-type="fig"} and Supplementary Table 5). The majority of MPCs (10/16 cases; 62.5%) showed high-level gain of the whole arm of chromosome 8q, regardless of histological grade, as previously reported [@b3]. Recurrent (*n* \> 1) focal (\< 2 Mb) amplifications containing known genes were identified on chromosomes 1p34.3--p34.2, 8p12--p11.21, 17q11.1--q21.2, and 20q13.13--q13.2 (Supplementary Table 5).

To determine whether MPCs would be underpinned by a pathognomonic somatic mutation, eight samples were subjected to targeted massively parallel sequencing comprising 273 genes, and 16 samples were subjected to Sequenom mutation profiling using the OncoCarta panel [@b22],[@b27]. We identified recurrent mutations affecting genes of the mitogen-activated protein kinase family (*MAP3K1* in three cases, and *MAP2K6* and *MAP3K4* in one case each) and recurrent splice-site mutations of *NBPF10* (*n =* 2) (Table[2](#tbl2){ref-type="table"}). A significant enrichment in genes mutated in luminal B breast cancers was observed in the constellation of mutations found in MPCs; out of the 119 genes most frequently mutated (ie ≥ 4 cases -- 3.5%) in luminal B IC-NSTs from The Cancer Genome Atlas (TCGA) study [@b16], *TP53* (W53^\*^), *PIK3CA* (H1047R), *CSMD2* (R3608S), *MAP3K1* (insertions and deletions in three cases), *ATRX* (P667T), *HMCN1* (A537G), *MLL2* (A946E), *SPEN* (ESS2280A), and *ZFHX4* (A2896S) were mutated in MPC samples (representation factor = 2.3; hypergeometric test *p* value \< 0.01; Table[2](#tbl2){ref-type="table"}). Sequenom analysis confirmed the results of the massively parallel sequencing analysis; of the hotspot mutations included in the OncoCarta panel, the *PIK3CA* H1047R mutation was identified in the MPC reported to have this mutation by massively parallel sequencing (MPC25). This mutation was also validated by Sanger sequencing (Supplementary Figure 2). In addition, *MAP3K1*, *MAP3K4*, *PIK3CA*, *NBPF10*, *CECR2*, and *CSMD2*, which were mutated in the MPCs analysed here, were also shown to be mutated in at least one of the four cases of pure and mixed MPC included in the TCGA study (<http://www.cbioportal.org/public-portal/study.do?cancer_study_id=brca_tcga_pub>, assessed on 3 December 2013). Taken together, our results suggest that MPCs are not driven by a pathognomonic mutation affecting any of the 273 genes included in our targeted capture massively parallel sequencing panel, and that genes mutated in luminal B IC-NSTs are also mutated in MPCs.

###### 

Somatic mutations identified by massively parallel sequencing in eight micropapillary carcinomas of the breast

  Gene        Mutation   Mutation type                        MAF      Depth   Tumour sample
  ----------- ---------- ------------------------------------ -------- ------- ---------------
  *AGFG2*     A443T      Non-synonymous coding                35.70%   366     MPC02T
  *AKT1*      E17K       Non-synonymous coding                31.70%   253     MPC06T
  *APC*       R2714L     Non-synonymous coding                4.80%    156     MPC25T
  *ATRX*      P667T      Non-synonymous coding                9.43%    156     MPC37T
  *CDC25B*    R137W      Non-synonymous coding                18.49%   799     MPC53T
  *CHD4*      N789I      Non-synonymous coding                6.90%    284     MPC06T
  *CSMD2*     R3608S     Non-synonymous coding                5.81%    149     MPC25T
  *CUBN*      N3576K     Non-synonymous coding                7.46%    204     MPC37T
  *DCHS2*     R434S      Non-synonymous coding                10.42%   147     MPC37T
  *DOCK11*    H833D      Non-synonymous coding                30.80%   132     MPC08T
  *DST*       P5601Q     Non-synonymous coding                7.81%    130     MPC10T
  *FBN1*      P83S       Non-synonymous coding                16.00%   273     MPC53T
  *FOXA1*     Y259D      Non-synonymous coding                23.80%   179     MPC06T
  *FOXA1*     P248S      Non-synonymous coding                10.30%   246     MPC06T
  *GPR98*     L3724F     Non-synonymous coding                23.74%   330     MPC53T
  *HMCN1*     A537G      Non-synonymous coding                13.60%   76      MPC10T
  *MAP1A*     S604^\*^   Stop gained                          38.70%   47      MPC10T
  *MAP2K6*    S35P       Non-synonymous coding                18.40%   273     MPC53T
  *MAP3K4*    G743R      Non-synonymous coding                29.90%   459     MPC53T
  *MLL2*      A946E      Non-synonymous coding                6.10%    207     MPC08T
  *MST1L*     W378G      Non-synonymous coding                23.28%   354     MPC25T
  *PIK3CA*    H1047R     Non-synonymous coding                64.80%   111     MPC25T
  *RBBP8*     R805L      Non-synonymous coding                4.40%    216     MPC08T
  *NBPF10*    --         Splice site donor                    37.50%   43      MPC02T
  *NBPF10*    --         Splice site donor                    28.10%   50      MPC25T
  *SHROOM4*   P769S      Non-synonymous coding                21.05%   398     MPC53T
  *SRCAP*     V2835M     Non-synonymous coding                20.59%   137     MPC37T
  *TP53*      W53^\*^    Stop gained                          55.30%   647     MPC53T
  *ZFHX4*     A2896S     Non-synonymous coding                6.20%    237     MPC08T
  *MAP3K1*    R271fs     Indel -- frameshift -- exon          31.58%   312     MPC02T
  *MAP3K1*    K1037fs    Indel -- frameshift                  40.00%   168     MPC02T
              L1491LQP   Indel -- codon insertion             32.14%   263     MPC06T
  *ATN1*      Q488QQ     Indel -- codon insertion             26.67%   88      MPC10T
  *SPEN*      ESS2280A   Indel -- codon change and deletion   34.62%   91      MPC11T
  *MAP3K1*    T918fs     Indel -- frameshift                  26.21%   183     MPC25T
  *MAP3K1*    F884fs     Indel -- frameshift                  37.50%   147     MPC25T

MAF, mutant allelic frequency; --, splice site.

Identification of expressed fusion transcripts in MPCs
------------------------------------------------------

RNA sequencing of five frozen MPCs resulted in a total amount of sequencing per sample of 1.33--1.92 Gb per lane, median 1.37 Gb per lane (Supplementary Table 6). Fusion transcript detection using ChimeraScan [@b37] identified 18 high-confidence chimeric transcripts in four MPCs (MPC10, MPC08, MPC71, and MPC72; [Figure 1](#fig01){ref-type="fig"} and Table[3](#tbl3){ref-type="table"}). In MPCs harbouring expressed fusion genes, the number of nominated high-confidence chimeras ranged from 11 in MPC10 to one in MPC72. MPC70 had no nominated high-confidence chimeric transcripts; no differences in the total number of aligned reads were found between cases that expressed fusion genes and those that did not (data not shown). Nominated chimeric transcripts were subsequently validated in each index case by RT-PCR and Sanger sequencing ([Figure 2](#fig02){ref-type="fig"}), of which eight of the 17 fusions were validated (Table[3](#tbl3){ref-type="table"}). qRT-PCR was used to confirm expression of in-frame fusion genes (Supplementary Figure 3). One or both of the partner genes involved in seven of the eight fusion genes were amplified as defined by aCGH analysis ([Figure 1](#fig01){ref-type="fig"} and Table[3](#tbl3){ref-type="table"}). Of the eight validated fusions, two were predicted to be in-frame (*SLC2A1--FAF1* and *BCAS4--AURKA*) and were both present in a single tumour (ie MPC10; [Figure 2](#fig02){ref-type="fig"} and Supplementary Figure 3). Both of these fusions were found to map to breakpoints of amplification (Table[3](#tbl3){ref-type="table"}).

###### 

Identification of expressed chimeric transcripts in five micropapillary breast carcinomas

  Sample ID   Gene 5′      Gene 3′      Mapping 5′       Mapping 3′       Total reads   Spanning reads   In frame   Validated   Copy number 5′   Copy number 3′
  ----------- ------------ ------------ ---------------- ---------------- ------------- ---------------- ---------- ----------- ---------------- ----------------
  MPC10       *ELMO2*      *RAE1*       chr20:45014762   chr20:55943760   25            14               No         Y           Gain             Amp
  MPC10       *BCAS4*      *AURKA*      chr20:49411466   chr20:54944444   24            1                Yes        Y           Gain             Amp
  MPC10       *SLC2A1*     *FAF1*       chr1:43424304    chr1:50906934    12            5                Yes        Y           Amp              Gain
  MPC10       *TSEN54*     *UNC84A*     chr17:73512608   chr7:934970      7             0                No         N           Gain             Gain
  MPC10       *CD46*       *USH2A*      chr1:207925401   chr1:215796235   6             1                No         Y           Amp              Gain
  MPC71       *LASP1*      *CDK12*      chr17:37026111   chr17:37646809   5             4                No         Y           Amp              Amp
  MPC10       *DENND1C*    *SURF1*      chr19:6470305    chr9:136218665   4             0                Yes        N           No change        No change
  MPC10       *UBE2V1*     *SULF2*      chr20:48713208   chr20:46286150   4             1                No         Y           Amp              Amp
  MPC08       *BC018860*   *CDK5RAP3*   chr1:566461      chr17:46052524   3             1                No         N           No change        No change
  MPC10       *LRRC6*      *HPRG1*      chr8:133584447   chr8:133572744   3             0                No         N           Amp              Amp
  MPC08       *PDLIM5*     *TCEB1*      chr4:95373037    chr8:74858633    3             3                No         N           No change        Amp
  MPC08       *TSPAN14*    *DYDC2*      chr10:82214037   chr10:82126443   3             1                No         N           Amp              No change
  MPC10       *IFI44L*     *IFI44*      chr1:79086087    chr1:79115476    2             0                No         N           Loss             Loss
  MPC10       *MRPL21*     *BX640963*   chr11:68660870   chr2:69686413    2             0                No         N           No change        No change
  MPC10       *SYNGAP1*    *RALY*       chr6:33387846    chr20:32664833   2             0                No         N           Gain             Gain
  MPC72       *MUC1*       *C1orf86*    chr1:155161501   chr1:2115916     2             0                No         N           Gain             Loss
  MPC71       *CYB5B*      *CALB2*      chr16:69458497   chr16:71416621   2             2                No         Y           No change        No change
  MPC71       *NSF*        *C17orf57*   chr17:44668037   chr17:45438743   2             2                No         Y           Amp              No change

5′, 5′ partner gene; 3′, 3′ partner gene; total reads, total number of reads supporting the nominated fusion; spanning reads, number of reads spanning the fusion junction.

Copy number derived from smoothed cbs ratios of aCGH data; loss, copy number loss; no change, no copy number change; gain, copy number gain, amp, amplification.

![Structure of validated high-confidence fusion genes in micropapillary carcinomas. Sanger sequencing validation of functionally assessed fusion genes in the index cases of micropapillary carcinomas (MPCs) (*BCAS4--AURKA* and *SLC2A1--FAF1* in MPC10 and *LASP1-CDK12* in MPC71). (A) Haematoxylin and eosin (H&E) and epithelial membrane antigen (EMA) staining of representative areas of the MPCs harbouring the *BCAS4--AURKA*, *SLC2A1--FAF1*, and *LASP1--CDK12* fusion genes (10× original magnification). (B) Schematic representation of nominated fusion transcripts. Fusion junctions with respective exon numbers are shown, while paler colours indicate 3′ and 5′ UTRs. (C) cDNA level sequence chromatograms spanning the junction (dotted line) of the fusion transcript.](path0232-0553-f2){#fig02}

RT-PCR analysis of a series of 14 independent MPCs and 62 IC-NSTs (Supplementary Table 1 and Supplementary Figure 4) revealed no additional case harbouring these fusion transcripts. Of interest, however, both *SLC2A1--FAF1* and *BCAS4--AURKA* fusion genes were found to be present in the lymph-node metastasis of the index case MPC10 (Supplementary Figure 3). We next sought to determine whether one or both partner genes of all validated chimeric transcripts would be involved in fusion genes in other breast cancers. Publicly available next-generation sequencing breast cancer datasets (*n =* 185) [@b12],[@b15]--[@b17],[@b41]--[@b43] were interrogated and revealed that *BCAS4* is the 5′ partner gene in the validated fusion *BCAS4--BCAS3* in MCF7 cells [@b13],[@b17] and that *FAF1* is involved in a DNA rearrangement in an ER-negative/HER2-negative primary breast cancer. None of the other genes of these in-frame fusions were found to be involved in previously reported fusion genes in breast cancers. Of the out-of-frame validated chimeras, we identified recurrent expressed chimeric transcripts involving *CDK12* (2.7%) and *RAE1* (1%), and DNA rearrangements involving *C17ORF57* (0.5%), *NSF* (0.5%), *USH2A* (0.5%), and *LASP1* (1%) from unselected breast cancers in external datasets [@b12],[@b15]--[@b17],[@b41]--[@b43] (Supplementary Table 7).

Assessment of the biological relevance of selected fusion genes identified in MPCs
----------------------------------------------------------------------------------

Given that *SLC2A1--FAF1* and *BCAS4--AURKA* fusion genes were present in both the primary tumour and lymph node metastasis of MPC10, we hypothesized that, albeit restricted to a single case, these fusion genes could constitute driver events. Therefore, the chimeric transcript and each partner gene were transiently expressed in four ER-positive/HER2-negative breast cancer cell lines, including MCF7, which is reported to recapitulate many of the phenotypic characteristics of MPCs [@b44]. Forced expression of *SLC2A1--FAF1* caused a significant increase in cell proliferation compared with the empty vector control (as measured by fold change in cell viability on day 9 in each cell line; [Figure 3](#fig03){ref-type="fig"}A) in two out of four cancer cell lines (ie MCF7 and BT474, *p* \< 0.05, one-way ANOVA). Forced expression of full-length *FAF1* had a similar effect only in MCF7 and BT474 cells ([Figure 3](#fig03){ref-type="fig"}A). *BCAS4--AURKA* forced expression caused a significant increase in cell proliferation, compared with the empty vector, in one cell line (MCF7, *p* \< 0.05, one-way ANOVA). Again, forced expression of the 3′ partner, *AURKA*, recapitulated these results only in MCF7 ([Figure 3](#fig03){ref-type="fig"}B). These data suggest that some private, or low-frequency, fusion genes may provide a selective advantage, which may also be dependent on the phenotype and genetic make-up of the cell harbouring them ([Figure 3](#fig03){ref-type="fig"}C).

![Functional assessment of in-frame expressed fusion genes. To determine the biological significance of the in-frame fusion genes identified in MPCs, forced expression of each fusion gene (*SLC2A1--FAF1*, A and *BCAS4--AURKA*, B), the 3′ partner gene, and an empty vector was performed in a panel of breast cancer cell lines. The fold change in cell population (*y*-axis) is plotted against growth time (days, *x*-axis). Red, solid black, and dashed black lines denote growth curves following transfection with fusion gene constructs (ie *SLC2A1--FAF1* or *BCAS4--AURKA*), full-length 3′ partner genes (ie *FAF1* or *AURKA*), and empty vector (pCMV), respectively. Western blotting using anti-DDK antibody was employed to confirm exogenous expression of cDNA constructs following transfection in MCF7 cells (A and B). In A and B, statistically significant differences are highlighted with an asterisk. (C) A matrix illustrating the pathological phenotype and aberrations affecting endogenous fusion gene partners in the cell lines employed, where dark blue squares represent positivity in a marker, light blue squares represent negativity in a marker, green squares denote amplification of a gene, and red denotes rearrangement of a gene.](path0232-0553-f3){#fig03}

Out-of-frame fusion genes may provide a selective advantage to cancer cells harbouring them by disrupting the expression of genes with tumour suppressor roles [@b45],[@b46]. Given that *CDK12* maps to the smallest region of amplification of the *HER2* amplicon, and recurrent fusions were identified in 13% (6/47) *HER2*-amplified tumours (Supplementary Table 7), we hypothesized that disruptions involving *CDK12* were due to a copy number breakpoint within the amplicon. By mining aCGH and matched gene expression data from *HER2*-amplified cells lines [@b47], we identified 7/14 *HER2*-amplified cells where a breakpoint within the *HER2* amplicon mapped to *CDK12* (Supplementary Table 4). A significant reduction in *CDK12* mRNA expression was observed in these cell lines relative to *HER2*-amplified breast cancer cell lines that did not harbour a breakpoint involving *CDK12* ([Figure 4](#fig04){ref-type="fig"}A; *p* = 0.0360, *t*-test). Assessment of CDK12 protein expression in this panel of cells revealed a significantly lower level of protein expression (*p* = 0.0438, *t*-test; [Figure 4](#fig04){ref-type="fig"}B), with MDA-MB-453 showing no detectable levels of CDK12 protein expression. CDK12 has recently been reported to be involved in the maintenance of genomic stability through regulation of genes involved in the DNA damage response pathway including *BRCA1*, *ATR*, *FANCI*, and *FANCD2*, and cells devoid of CDK12 have been reported to be sensitive to DNA-damaging agents [@b48]. To determine whether *HER2*-amplified cells with breakpoints in *CDK12* were sensitive to PARP inhibitors, we investigated the sensitivity of *HER2*-amplified and ER-positive breast cancer cell lines to BMN673 ([Figure 4](#fig04){ref-type="fig"}C) and olaparib (Supplementary Figure 5). Although there was no difference in sensitivity comparing the SF50 to cell lines with and without CDK12 disruption (*p* = 0.207, BMN673 and *p* = 0.375, olaparib, *t*-test), MDA-MB-453 cells that are null for CDK12 expression were sensitive to both BMN673 and olaparib. Silencing of CDK12 mediated by siRNA in ER-positive cell lines MCF7 and T47D resulted in increased sensitivity to the PARP inhibitor BMN673 ([Figure 4](#fig04){ref-type="fig"}D). Furthermore, the ability to elicit RAD51 foci formation upon treatment with ionizing radiation or the PARP inhibitor BMN673 was diminished upon CDK12 silencing ([Figure 4](#fig04){ref-type="fig"}E and Supplementary Figure 6). Reconstitution of wild-type CDK12 in MDA-MB-453 CDK12 null cells rendered cells more resistant to both BMN673 ([Figure 4](#fig04){ref-type="fig"}F) and olaparib (Supplementary Figure 5).

![Disruption of *CDK12* leads to PARP inhibitor sensitivity. (A) mRNA expression of CDK12 in *HER2*-amplified cell lines with a breakpoint spanning the *CDK12* locus shows significantly lower levels of *CDK12* mRNA compared with cells without a breakpoint spanning *CDK12*. (B) Western blot analysis of endogenous CDK12 in a panel of *HER2*-amplified cell lines relative to β-actin loading control. BT474 (blue) was employed as a loading control for normalization of the results of the western blot. Note that MDA-MB-453 shows no CDK12 expression (red), and relative quantification of CDK12 protein expression relative to β-actin, showing a significantly lower level of expression in cell lines with a breakpoint spanning *CDK12* than those without (*p* = 0.0438, *t*-test). (C) Log~10~ SF50 of *HER2*-amplified cell lines to the PARP inhibitor BMN673. SUM149 in blue as a positive control, given that this cell line harbours a *BRCA1* mutation. (D) CDK12 silencing results in increased sensitivity to BMN673 in T47D and MCF7 ER-positive breast cancer cells. The *BRCA1* mutant SUM149 cells displayed no increase in sensitivity upon CDK12 silencing, suggesting that the PARP inhibitor sensitivity caused by silencing of this gene results from impaired homologous recombination DNA repair. Western blot showing expression of CDK12 in T47D, MCF7, and SUM149 cells relative to β-actin loading control. (E) Percentage of cells with RAD51 positive foci normalized to phospho-γ-H2AX foci formation without treatment (Ctrl), 6 h after 10 Gy (IR) of irradiation, and with 1 m[m]{.smallcaps} BMN673 for 24 h (PARPi), with (red) and without (grey) CDK12 silencing. (F) Reconstitution of full-length CDK12 (blue) and empty vector (p.CMV) (black) in MDA-MB-453 cells treated with BMN673. Western blot showing expression of CDK12 in MDA-MB-453 cells transfected with full-length CDK12.](path0232-0553-f4){#fig04}

Taken together, our results demonstrate that MPCs do not harbour highly-recurrent fusion genes; however, some of the in-frame private fusion genes identified in this study have a biological impact that is likely to be context-dependent and may be part of a convergent phenotype. Loss of CDK12 due to breakpoints in the *HER2* amplicon results in sensitivity to PARP inhibitors, suggesting that some out-of-frame fusion genes may represent bona fide loss-of-function genomic events, and potentially targetable somatic genetic aberrations.

Discussion
==========

In this analysis of breast MPCs, not only have we confirmed the patterns of gene copy number aberrations previously reported by our group [@b2],[@b3] in this special type of breast cancer, but we have also provided direct evidence to rule out two potential mechanisms that result in breast cancers displaying a micropapillary phenotype: (i) pathognomonic mutations in genes recurrently mutated in breast cancer and DNA repair-related genes and (ii) highly-recurrent expressed fusion genes. In fact, our analysis revealed recurrent mutations affecting MAPK genes. In addition, mutations affecting genes often mutated in luminal B IC-NSTs have also been found in individual MPC samples (Table[2](#tbl2){ref-type="table"}). This finding confirms our previous observation that MPCs have a constellation of genetic aberrations similar to those of luminal B breast cancers [@b2],[@b3] and rules out the possibility that the MPC phenotype is driven by pathognomonic mutations affecting any of the 273 recurrently mutated breast cancer and DNA repair-related genes included in the targeted capture sequencing platform employed (Supplementary Table 3) and in the Sequenom OncoCarta panel. Furthermore, paired-end massively parallel RNA-sequencing revealed that although fusion genes are present in a proportion of MPCs, these constitute private genetic events (ie restricted to the index case) and often map to regions of amplification.

Two of the in-frame expressed fusion genes identified in this study, *SLC2A1--FAF1* and *BCAS4--AURKA*, were present both in the primary tumour MPC10 and in the corresponding synchronous lymph-node metastasis (MPC10LND). Although this observation may merely indicate that these fusion genes were present in the modal clonal population of MPCs, it is possible that their maintenance in the metastatic deposit was due to a selective advantage conferred by the expression of the chimeric fusion genes. To test whether these fusion genes would confer a growth/survival advantage, we forced the expression of the chimeric fusion transcripts and each 3′ partner in four ER-positive, HER2-negative breast cancer cell lines. Similar to driver fusion genes identified by RNA sequencing analysis of breast cancer [@b17], ectopic overexpression of these in-frame fusion genes resulted in increased proliferation of multiple breast cancer cell lines, which was similar to the effect of the ectopic expression of the 3′ partner genes. It should be noted, however, that different ER-positive breast cancer cell lines responded differently to the forced expression of the fusion genes *SLC2A1--FAF1* and *BCAS4--AURKA*, and their wild-type fusion gene partners ([Figure 3](#fig03){ref-type="fig"}). The *SLC2A1--FAF1* fusion involves a promoter swap of the major glucose transporter *SLC2A1* exon 1 fused to exons 13--16 of *FAF1. FAF1* (FAS associate factor 1) encodes for a protein that binds to FAS antigen and initiates apoptosis; its down-regulation may contribute to tumourigenesis, through the regulation of apoptosis and NFκB activity, as well as in ubiquitination and proteasomal degradation [@b49]. The fusion gene found in MPC10 contains the ubiquitin association and ubiquitin-like regulatory X domain [@b49]. The *BCAS4--AURKA* fusion gene results in the preservation of the AURKA kinase domain being driven by the promoter sequences of *BCAS4*. The loci of *BCAS4* and *AURKA* (ie 20q13) are amplified in MPC10 and in MCF7 cells. *AURKA* encodes for Aurora Kinase A, a serine-threonine kinase mainly involved in centrosome duplication, mitotic entry, and spindle assembly [@b50]. Although *AURKA* gene amplification is a common genetic aberration in breast cancer [@b16], its role as a therapeutic target for breast cancers harbouring amplification of this locus remains to be fully established. Taken together, these findings suggest that some private fusion genes may provide a growth/survival advantage to cancer cells and that this advantage is context-dependent and may be the product of epistatic interactions.

Some of the partner genes of the validated chimeric transcripts found in the present study were shown to be involved in other somatic rearrangements in breast cancers. *CDK12*, *LASP1*, *RAE1*, *C17orf57*, *NSF*, and *USH2A* were partners of out-of-frame, but not in-frame, fusion genes here and in other massively parallel sequencing analyses of breast cancers [@b12],[@b15]--[@b17],[@b41]--[@b43] (Supplementary Table 7). It is plausible that these out-of-frame rearrangements result in loss of function of one or both partners involved. Re-analysis of publicly available data revealed that *CDK12* may constitute a tumour suppresser gene as it is recurrently targeted not only by DNA rearrangements in breast (2.6% of unselected breast cancers; 13% of *HER2*-amplified breast cancers) and 1/17 (5%) *HER2*-amplified gastric cancers [@b51], but also by nonsense mutations in 1.5% of triple-negative breast cancers [@b43]. Consistent with this notion, CDK12 has been shown to be related to DNA repair, given that it plays a role in the regulation of transcription. In addition, depletion of CDK12 results in decreased expression of predominantly long genes with high numbers of exons, in particular DNA damage response genes, including *BRCA1*, *ATR*, *FANCI*, and *FANCD2*. CDK12-deficient cells display spontaneous DNA damage and are sensitive to a variety of DNA-damaging agents [@b48]. Here we have demonstrated that RNA-interference-mediated silencing of CDK12 in ER-positive cell lines resulted in increased sensitivity to PARP inhibition and a reduction in the ability to form RAD51 foci in the nucleus upon DNA damage through irradiation or PARP inhibition. Furthermore, MDA-MB-453 cells, which lack CDK12, displayed sensitivity to PARP inhibition, which was rescued upon re-expression of full-length CDK12. These observations suggest that the subset of *HER2*-amplified breast cancers harbouring a disruption of *CDK12* through somatic rearrangements may benefit from treatment with PARP inhibitors, and provide a molecular rationale for the testing of these agents in HER2-positive disease.

This study has several limitations. First, the small number of cases subjected to mRNA sequencing could have resulted in a type II/β-error in the search of a highly-recurrent pathognomonic event; however, by the sequencing of five samples we should have been able to identify a recurrent event (ie with a prevalence similar to *FOXL2* mutations in granulosa cell tumours of the ovary [@b52]) with 97% statistical power. Second, although cell lines constitutively harbouring the in-frame fusion genes identified in primary MPCs were not available, our results demonstrate that forced expression of *SLC2A1--FAF1* and *BCAS4--AURKA* results in increased growth/survival in multiple breast cancer cells.

In conclusion, our findings demonstrate that the MPC phenotype in breast cancers is neither driven by pathognomonic mutations affecting the 273 recurrently mutated breast cancer and DNA repair-related genes tested in this study, nor is it underpinned by a highly-recurrent pathognomonic expressed fusion gene. Although the fusion genes identified in this study were private events, we have provided circumstantial evidence to suggest that at least some private in-frame expressed fusion genes may also be driver events and impact on cancer cell proliferation. Finally, some of the out-of-frame *CDK12* rearrangements in HER2-positive breast cancers were shown to lead to a potential loss of function and provide a rationale for treating a subset of *HER2*-amplified patients with PARP inhibitors.
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